Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment ...

Nanomedicine. 2014;9(1):105-120. Overall, HDL-based siRNA delivery possesses many attractive features, including ultra-small size, favorable surface properties (no PEGylation is required for achieving ...

A study published in the Journal of Controlled Release ("NMR-based analysis of impact of siRNA mixing conditions on internal structure of siRNA-loaded LNP"), led by Assistant Professor Keisuke Ueda ...

In a new study published in the Clinical and Translational Medicine, the research group of Prof. Chen-Yu Zhang and Prof. Xi Chen at Nanjing University evaluated the on- and off-target effects of ...

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce a new agreement with AstraZeneca, a global ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and implications for molecular biology research.

In Parkinson’s disease, α-synuclein accumulates in neurons and may thereby contribute to their degeneration. Reducing expression of α-synuclein may be an effective therapy, but delivering short ...

TAMs are crucial immune cells in the tumor microenvironment and key targets for tumor immunotherapy, with gene therapy being an important approach. However, existing gene carriers are unsatisfactory ...

Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN ...

Table 2. Stable nucleic acid lipid particle formulations. Stable nucleic acid lipid particle formulations in systemic delivery Target siRNA and modification (yes/no) Animal model Ref.